KIR2DL2/2DL3-E 35 alleles are functionally stronger than-Q 35 alleles

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Bari, Rafijul ^a   Thapa, Rajoo ^a   Bao, Ju ^a   Li, Ying ^a   Zheng, Jie ^a   Leung, Wing ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; GLUTAMINE; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KIR2DL2 PROTEIN, HUMAN; KIR2DL3 PROTEIN, HUMAN; PROTEIN BINDING;

ALLELE; ANIMAL; CELL LINE; CHEMISTRY; CYTOLOGY; CYTOTOXICITY; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HUMAN; IMMUNOLOGY; MOLECULAR MODEL; MOUSE; NATURAL KILLER CELL; NONOBESE DIABETIC MOUSE; PRIMARY CELL CULTURE; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; SCID MOUSE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ANIMALS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION; GENOTYPE; GLUTAMIC ACID; GLUTAMINE; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; MICE, SCID; MODELS, MOLECULAR; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY CELL CULTURE; PROTEIN BINDING; PROTEIN DOMAINS; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, KIR2DL2; RECEPTORS, KIR2DL3; SIGNAL TRANSDUCTION;

EID: 84962838941     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23689     Document Type: Article

References (38)

1. Chan, W. K. et al. Multiplex and genome-wide analyses reveal distinctive properties of KIR + and CD56 + T cells in human blood. J. Immunol. 191, 1625-1636 (2013).
2. Andersson, S., Fauriat, C., Malmberg, J. A., Ljunggren, H. G., Malmberg, K. J. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 114, 95-104 (2009).
3. Cichocki, F., Miller, J. S., Anderson, S. K. Killer immunoglobulin-like receptor transcriptional regulation: a fascinating dance of multiple promoters. J Innate Immun. 3, 242-248 (2011).
4. Traherne, J. A. et al. Mechanisms of copy number variation and hybrid gene formation in the KIR immune gene complex. Hum Mol Genet. 19, 737-751 (2010).
5. Leung, W. Infusions of allogeneic natural killer cells as cancer therapy. Clin Cancer Res. 20, 3390-3400 (2014).
6. Pyo, C. W. et al. Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. PLoS One. 5, e15115 (2010).
7. Wilson, M. J. et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc. Natl. Acad. Sci. USA 97, 4778-4783 (2000).
8. Hsu, K. C., Chida, S., Geraghty, D. E., Dupont, B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev. 190, 40-52 (2002).
9. Moesta, A. K. et al. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J. Immunol. 180, 3969-3679 (2008).
10. Schonberg, K., Sribar, M., Enczmann, J., Fischer, J. C., Uhrberg, M. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 117, 98-107 (2011).
11. Bari, R. et al. Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 114, 5182-5190 (2009).
12. Yawata, M. et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med. 203, 633-645 (2006).
13. Carr, W. H., Pando, M. J., Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J. Immunol. 175, 5222-5229 (2005).
14. Frazier, W. R., Steiner, N., Hou, L., Dakshanamurthy, S., Hurley, C. K. Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand. J. Immunol. 190, 6198-6208 (2013).
15. Valiante, N. M. et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7, 739-751 (1997).
16. Kim, S. et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 436, 709-713 (2005).
17. Vilches, C., Castano, J., Gomez-Lozano, N., Estefania, E. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens. 70, 415-22 (2007).
18. Robinson, J. et al. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 43, D423-431 (2015).
19. Bari, R. et al. Molecular determinant-based typing of KIR alleles and KIR ligands. Clin Immunol. 138, 274-281 (2011).
20. Bari, R. et al. Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 31, 3782-3790 (2013).
21. Snyder, G. A., Brooks, A. G., Sun, P. D. Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Proc. Natl. Acad. Sci. USA 96, 3864-3869 (1999).
22. Fan, Q. R., Long, E. O., Wiley, D. C. A disulfide-linked natural killer cell receptor dimer has higher affinity for HLA-C than wildtype monomer. European journal of immunology 30, 2692-2697 (2000).
23. Kulkarni, S., Martin, M. P., Carrington, M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol. 20, 343-352 (2008).
24. Hollenbach, J. A. et al. Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand. Immunogenetics 61, 663-671 (2009).
25. Lorentzen, A. R. et al. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol. 65, 658-666 (2009).
26. Middleton, D., Diler, A. S., Meenagh, A., Sleator, C., Gourraud, P. A. Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens. 73, 553-560 (2009).
27. Lowe, D. P., Cook, M. A., Bowman, S. J., Briggs, D. C., Group, UKSsI. Association of killer cell immunoglobulin-like receptors with primary Sjogren's syndrome. Rheumatology (Oxford) 48, 359-362 (2009).
28. Toloza, S. et al. Association of killer cell immunoglobulin-like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus. Lupus. 17, 793-798 (2008).
29. Levinson, R. D. et al. Combination of KIR and HLA gene variants augments the risk of developing birdshot chorioretinopathy in HLA-A, 29-positive individuals. Genes Immun. 9, 249-258 (2008).
30. Majorczyk, E. et al. Associations of killer cell immunoglobulin-like receptor genes with complications of rheumatoid arthritis. Genes Immun. 8, 678-83 (2007).
31. Arnheim, L., Dillner, J., Sanjeevi, C. B. A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. Tissue Antigens. 65, 252-259 (2005).
32. Momot, T. et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 50, 1561-1565 (2004).
33. Suzuki, Y. et al. Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Invest Dermatol. 122, 1133-1136 (2004).
34. Estefania, E. et al. Influence of KIR gene diversity on the course of HSV-1 infection: resistance to the disease is associated with the absence of KIR2DL2 and KIR2DS2. Tissue Antigens. 70, 34-41 (2007).
35. Jennes, W. et al. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J. Immunol. 177, 6588-6592 (2006).
36. Bari, R., Schell, S., Tuggle, M., Leung, W. An Improved Method With High Specificity for KIR2DL1 Functional Allele Typing. Laboratory medicine 46, 207-213 (2015).
37. Case, D. A. et al. AMBER 12. University of California: San Francisco (2012).
38. Boyington, J. C., Motyka, S. A., Schuck, P., Brooks, A. G., Sun, P. D. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 405, 537-543 (2000).